Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Cambridge Heart

This article was originally published in The Gray Sheet

Executive Summary

Cambridge Heart: Non-invasive cardiac diagnostics firm receives $3.5 mil. from a private placement of convertible preferred stock to Morgan Stanley Venture Capital Fund II, L.P., and "certain related funds." Bedford, Massachusetts-based Cambridge Heart is conducting clinical trials of its CH 2000 exercise stress test system, which the company says can screen patients at risk for sudden cardiac death. The company says it has filed a 510(k) for FDA clearance of the CH 2000 and has inked letter-of-intent agreements for distribution with Fukuda Denshi in Japan and Kontron Instruments in Europe. Founded in 1992, Cambridge Heart has raised $10 mil. to date...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel